Page 122 - Drug Class Review
P. 122
Page 91 of 205
Drug Effectiveness Review Project
placebo 25% (at least 3 incidences/event) 2% Cold syndrome was reported more frequently in DON-treated patients (P < 0.05) placebo NR 5%
donepezil 40% (at least 3 incidences/event) 7% Post randomization exclusions: Yes (5) Overall loss to follow-up: 15% Loss to follow-up differential high: Unable to assess Donepezil NR 1%
ITT: Yes NR NR NR Fair
Final Report Update 1 Authors: Homma et al. Year: 2000 ADVERSE EVENTS: Overall adverse effects reported: Cold syndrome • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
